New HIV Vaccine Candidate Shows Promise In Early Trials

Despite the trial's early success, it was halted due to a non-life-threatening allergic reaction in one participant.

A new HIV vaccine candidate has shown promise in early-stage clinical trials, successfully generating broadly neutralising antibodies in a small number of people.

Broadly neutralising antibodies (bnAbs) are antibodies that can recognise and neutralise multiple strains of HIV. They have been seen as a potential key to an HIV vaccine but have been difficult to generate in humans.The research has been published in Cell.

The new vaccine candidate, DHVI, was tested in a small clinical trial. The trial showed that the vaccine was able to generate bnAbs in several people after two doses.